Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Repare Therapeutics Inc. - Common Shares (NQ: RPTX )

1.250 -0.080 (-6.02%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Repare Therapeutics Inc. - Common Shares

< Previous 1 2 3 4 5 6 Next >
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Good morning, investors! It's time to start another day of trading with the biggest pre-market stock movers for Thursday! 
Via InvestorPlace
24 Stocks Moving in Thursday's Pre-Market Session
Gainers Immix Biopharma, Inc. (NASDAQ: IMMX) rose 42.2% to $2.63 in pre-market trading after declining around 14% on Wednesday. Immix Biopharma, last month, announced positive interim data from an... 
Via Benzinga
Repare Therapeutics Shares Dip After Updated RP-3500 Data In Solid Tumors
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers 
Via Benzinga
Repare Therapeutics Announces a Worldwide License and Collaboration Agreement with Roche for Camonsertib (RP-3500)
From Repare Therapeutics Inc.
Via Business Wire
30 Stocks Moving In Monday's Mid-Day Session
Gainers Evolve Transition Infrastructure LP (NYSE: SNMP) shares rose 29.2% to $0.6699 after jumping around 14% on Friday. 
Via Benzinga
58 Biggest Movers From Yesterday
Gainers Catalyst Biosciences, Inc. (NASDAQ: CBIO) gained 234.2% to close at $1.27 after the company announced it sold its complement portfolio for $60 million. 
Via Benzinga
Repare Therapeutics to Participate at the 2022 Guggenheim Synthetic Lethality Day
From Repare Therapeutics Inc.
Via Business Wire
Repare Therapeutics Provides Business Update and Reports First Quarter 2022 Financial Results
From Repare Therapeutics Inc.
Via Business Wire
Repare Therapeutics Announces Publication of Preclinical Data in Nature Demonstrating the Potential of PKMYT1 Inhibitor RP-6306 in Tumors With CCNE1 Amplification
From Repare Therapeutics Inc.
Via Business Wire
The Daily Biotech Pulse: Aeglea Stock Jumps On Inherited Metabolic Disease Data, Partial Hold Lifted On Gilead's 2 Blood Trials, Early Data From Novartis' KRAS Inhibitor And More
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 12, 2022
Upgrades 
Via Benzinga
Repare Therapeutics Presents Updated Clinical Data from the Ongoing Phase 1/2 TRESR Study of RP-3500 Monotherapy in Solid Tumors at the 2022 AACR Annual Meeting
From Repare Therapeutics Inc.
Via Business Wire
The Week Ahead In Biotech (April 10-April 16): Regeneron FDA Decision, Cancer Conference Presentations And More
Biotech stocks managed to carve out modest gains for the week ending April 8, defying the broader market weakness. The defensive nature of the stocks make them appealing in times of risk aversion. 
Via Benzinga
Repare Therapeutics to Present New Clinical and Preclinical Data at the 2022 AACR Annual Meeting
From Repare Therapeutics Inc.
Via Business Wire
Repare Therapeutics Highlights Early RP-3500 Data In Solid Tumor Patients
Repare Therapeutics Inc (NASDAQ: RPTX) has announced the presentation of monotherapy dose selection and safety data from its Phase 1/2 TRESR trial of RP-3500.... 
Via Benzinga
Repare Therapeutics to Participate in Two Upcoming Virtual Investor Conferences
From Repare Therapeutics Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Friday
Before 10 am on Friday, 110 companies set new 52-week lows. Interesting Points From Today's 52-Week Lows: Humana (NYSE:HUM) was the biggest company on a market cap... 
Via Benzinga
Repare Therapeutics Provides Corporate Update and Highlights Key Milestones Anticipated in 2022
From Repare Therapeutics Inc.
Via Business Wire
Repare Therapeutics Expands Executive Leadership Team with the Appointment of Philip Herman as EVP Commercial & New Product Development
From Repare Therapeutics Inc.
Via Business Wire
Repare Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
From Repare Therapeutics Inc.
Via Business Wire
Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-6306 in Combination with Gemcitabine for the Treatment of Advanced Solid Tumors
From Repare Therapeutics Inc.
Via Business Wire
Repare Therapeutics Insiders Establish New and Modified Automatic Securities Disposition Plans
From Repare Therapeutics Inc.
Via Business Wire
Repare Therapeutics to Participate in Two Upcoming Virtual Investor Conferences
From Repare Therapeutics Inc.
Via Business Wire
Repare Therapeutics Provides Business Update and Reports Third Quarter 2021 Financial Results
From Repare Therapeutics Inc.
Via Business Wire
Repare Therapeutics Announces Closing of Upsized Offering of Common Shares and Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Repare Therapeutics Inc.
Via Business Wire
The Daily Biotech Pulse: Merck Reports Beat-And-Raise Quarter, Pfizer-BioNTech Snag Orders For Additional Vaccine Doses, HCW Cleared For Phase 1 Study Of Pancreatic Cancer Drug
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Corvus' China Partner Approved For Early Stage Study Of CPI-818 In... 
Via Benzinga
Repare Therapeutics Announces Pricing of Upsized Offering of Common Shares
From Repare Therapeutics Inc.
Via Business Wire
Repare Therapeutics Announces Proposed Public Offering of Common Shares
From Repare Therapeutics Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.